Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL PUMPSPRAY vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal elimination half-life of nitroglycerin is 1–4 minutes; however, clinical hemodynamic effects last longer due to active metabolites and tissue distribution.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Metabolized primarily in the liver by the enzyme glutathione nitrate reductase, and also by red blood cells and vascular smooth muscle. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate, which have minimal vasodilatory activity.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal excretion of inactive metabolites (nitrate ions) accounts for approximately 80% of elimination; biliary/fecal excretion is minimal (less than 5%).
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound, primarily to albumin.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
3.3 L/kg, indicating extensive extravascular distribution.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual spray: approximately 40% (due to first-pass metabolism in liver and gastrointestinal tissues after swallowing).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required for any degree of renal impairment.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Dose reduction may be needed in severe hepatic impairment (Child-Pugh C); start with lowest effective dose.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Safety and efficacy not established; not recommended for use in pediatric patients.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Initiate with lowest effective dose; increased sensitivity to hypotension due to age-related changes in baroreceptor reflexes.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Coadministration with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) is contraindicated due to the risk of severe hypotension, syncope, and myocardial ischemia.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension in patients with hypovolemia or low systolic blood pressure.,Hepatic impairment: Use with caution in patients with severe hepatic disease.,Headache: Common and may be severe; tolerance may develop.,Sublingual administration: Do not inhale; spray onto or under the tongue.,Overuse: Excessive use may result in tolerance and reduced efficacy.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis or cardiac tamponade
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol consumption as it may increase hypotensive effects. No specific food interactions; consult healthcare provider regarding dietary concerns.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association with major malformations. During second and third trimesters, use is reserved for acute hypertensive crises or pulmonary edema; potential risks include maternal hypotension leading to uteroplacental hypoperfusion and fetal hypoxia. Avoid near term due to risk of maternal hypotension and possible fetal distress.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
No human data on NTG excretion in breast milk. M/P ratio is unknown. Based on molecular weight (227.09 Da) and short half-life (1-3 min), transfer is likely minimal. Use with caution in breastfeeding only if clearly needed; monitor infant for hypotension or methemoglobinemia (rare).
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No systematic pharmacokinetic studies in pregnancy. Physiological changes (increased plasma volume, renal clearance) may alter distribution. No dose adjustment recommendations exist; use lowest effective dose. Initial dose: 1-2 sprays (0.4-0.8 mg) sublingually, repeat every 5 minutes up to 3 doses. Monitor for exaggerated hypotension due to decreased vascular resistance in pregnancy.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Nitrolingual Pumpspray (nitroglycerin) is a sublingual spray for acute angina. Onset of action is 1-3 minutes. Do not shake before use. Prime pump with 5 sprays if new or not used for 6 weeks. Avoid concurrent use of PDE5 inhibitors (e.g., sildenafil) due to severe hypotension. Monitor for hypotension, syncope, and headache. Tolerance develops with frequent use; provide nitrate-free interval.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Use 1-2 sprays at the first sign of angina, under the tongue, not inhaled.,Do not shake the bottle before use.,Prime the pump with 5 sprays if new or not used for 6 weeks.,Sit down when using to avoid fainting from low blood pressure.,Seek emergency if pain not relieved after 3 doses (5 minutes apart).,Avoid alcohol and erectile dysfunction drugs (e.g., sildenafil, tadalafil).
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL PUMPSPRAY vs MONOKET, answered by our medical review team.
NITROLINGUAL PUMPSPRAY is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL PUMPSPRAY and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL PUMPSPRAY is: 1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL PUMPSPRAY and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL PUMPSPRAY is classified as Category C. Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association wit. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.